A wide variety of drugs alter neural function. For many such agents -such as opiates, muscle relaxants and local anesthetics -the way they produce their effect is known. In these cases, pharmacologists have not only identified a receptor that binds the drug, but have also shown that altered receptor function accounts for the drug effect. The benefits of knowing a drug target are enormous: it enables screening for improved drugs, the analysis of drug interactions and the study of drug resistance. In contrast to these pharmacological success stories, targets have remained elusive for many of the drugs that induce hypnosis, sedation, or anesthesia. In large measure, this reflects the tendency of sedating drugs to bind weakly and broadly to cellular components. This makes it hard to trap a unique complex and hard to focus on a single drug-induced change. For these difficult cases, it has been long appreciated that a genetic approach could usefully complement biochemical and physiological analysis.
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The basic idea is that genetic variation in a significant drug target should be associated with an altered drug response. Although the implementation of this idea would seem straightforward, success has been a long time in coming. Multiplicity of drug targets, redundancy in target gene families, and compensatory gene expression have all undoubtedly contributed to the delay. A further obstacle has been the difficulty in distinguishing mutations that affect the target from those that alter a bypass pathway. But in the past year there have at last been two exemplary cases in which the genetic approach has demonstrated its power. In both cases the implicated target is an ion channel -a γ γ-amino-butyric acid (GABA)-gated chloride channel for the sedative effects of intravenous anesthetics [1] and a calcium-activated potassium channel for the locomotor effects of ethanol [2] -and in both cases the drugs produce their effects by increasing channel function.
Propofol and etomidate are two commonly used intravenous general anesthetics that have similar pharmacology. Prominent amongst the many actions produced by clinical concentrations of these drugs (1-5 µ µM) is the ability to increase chloride currents flowing through GABA-gated channels, an action that depresses neuronal excitability [3] . If this action were responsible for the sedative and hypnotic effects of these drugs, deletion of the gene encoding the target channel should render an organism insensitive to them. Accordingly, knockout mice bearing targeted disruptions of genes encoding subunits of GABA-gated chloride channels have been evaluated for sensitivity to propofol and/or etomidate.
The results of these studies were disappointingly modest, but this might only have been because some knockouts were too sick to test well and others were masked by compensatory expression of another channel The result of this experiment was all one could ask for. In contrast to the very sickly β β3 knockout mice [8], the β β3 knock-in mice were found to be healthy, but to have a much reduced sensitivity to propofol and etomidate [1]. Most dramatically, the mutant mice continued to display a normal motor response to a nociceptive stimulus despite the injection of either drug at levels more than sufficient to obliterate this reflex in wild-type mice. This single experiment provides the first definitive proof that, as long suspected, the GABA channel is the critical target for these intravenous anesthetics in mice and thus presumably in man. It further shows that, of the many different versions of this channel, those containing the β β3 subunit are the most important for drug action.
Dwarfing the study of intravenous anesthetics in both urgency and difficulty is the problem of identifying the targets by which ethanol influences the nervous system. The urgency comes from the huge personal and societal cost arising from use of this drug. The difficulty stems from the multiple changes caused by inebriating concentrations of ethanol (>5 mM), making it very hard to sort out pertinent from incidental effects. Consequently, there has been a long and serious investment in genetic studies of alcohol effects in laboratory animals. This has involved both breeding/selection schemes to identify quantitative trait loci (QTL) 
